Eli Lilly & Co. stock (US5324571083): licensing deal with Hanmi highlights pipeline expansion

Eli Lilly & Co. shares on the New York Stock Exchange traded slightly higher on 06/01/2026 as the US drug maker signed a licensing agreement worth up to USD 1.26 billion with South Korea’s Hanmi Pharm for a GLP-2 analog, underscoring its strategy to broaden its gastroenterology pipeline.

Eli Lilly & Co. shares on the New York Stock Exchange traded modestly higher on 06/01/2026 after the US pharmaceutical group announced a licensing agreement with Hanmi Pharm for the experimental GLP-2 analog sonefpeglutide, a move that underpins its strategy to broaden its gastroenterology and metabolic disease franchise, according to Pharmaphorum on 05/31/2026 and Pharmaceutical Technology on 05/31/2026.

Under the deal, Lilly is paying an upfront fee of USD 75 million and has agreed to potential milestone payments of up to USD 1.185 billion tied to clinical, regulatory and commercial milestones, bringing the total potential value of the transaction to USD 1.26 billion, according to coverage from FirstWord Pharma on 05/31/2026.

The transaction gives Lilly exclusive rights to develop and commercialize sonefpeglutide outside South Korea, where Hanmi retains rights, and is focused initially on short bowel syndrome and potentially other gastrointestinal indications, as reported by Pharmaphorum and Pharmaceutical Technology on 05/31/2026.

The stock traded around the USD 800 mark on 06/01/2026 on the NYSE under the ticker LLY, keeping Eli Lilly among the most valuable constituents of major US indices such as the S&P 500, according to price data reported by major US financial news outlets on 06/01/2026.[ ]

In Germany, Eli Lilly shares were also quoted on Tradegate in euros on 06/01/2026, reflecting continued strong demand from European retail investors for exposure to large US biopharma names, according to German trading venue data cited by regional financial media on 06/01/2026.[ ]

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Eli Lilly & Co.
• Sector/industry: Pharmaceuticals and biotechnology with a focus on metabolic, oncology and immunology therapies
• Headquarters/country: Indianapolis, United States
• Core markets: United States, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Diabetes and obesity treatments, immunology drugs, oncology portfolio and other specialty medicines
• Home exchange/listing venue: New York Stock Exchange (LLY)
• Trading currency: USD

Eli Lilly & Co.: core business model

Eli Lilly operates as a global research-driven pharmaceutical company that develops, manufactures and markets prescription medicines, with revenue concentrated in chronic disease areas such as diabetes, obesity, immunology and oncology where it leverages late-stage innovation and large-scale commercial infrastructure.

What banks and research houses say about Eli Lilly & Co.

According to MarketBeat data as of 05/31/2026, the consensus rating on Eli Lilly & Co. from a broad group of Wall Street analysts is in the buy range with an average 12-month price target above the prevailing market price, based on MarketBeat’s compilation of brokerage research published through 05/31/2026.[ ]

Major US banks and global research houses have highlighted Lilly’s growth prospects around its diabetes and obesity therapies, as well as its expanding pipeline from transactions such as the new Hanmi licensing deal, while also pointing to valuation that already prices in a substantial portion of expected earnings growth, according to recent analyst commentary summarized by financial news outlets on 05/31/2026.[ ]

Conclusion

The new licensing agreement with Hanmi gives Eli Lilly & Co. access to a phase 2 GLP-2 analog that complements its existing presence in metabolic and gastrointestinal diseases while involving a staged financial commitment with milestones up to USD 1.26 billion.

For investors, the deal underscores Lilly’s continued appetite for external innovation to sustain its growth profile, a factor that features prominently in current analyst assessments of the LLY stock even as valuation remains a key discussion point among market observers.[ ]

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.